Livcilno M 10mg/25mg Tablet ER is a combination antihypertensive medication containing Cilnidipine 10mg and Metoprolol Succinate 25mg in an extended-release formulation. Cilnidipine is a calcium channel blocker that selectively inhibits L-type and N-type calcium channels, leading to vasodilation of peripheral arteries and reduction of sympathetic nervous system activity, thereby effectively lowering blood pressure. Metoprolol Succinate is a beta-1 selective adrenergic receptor blocker that decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and providing cardioprotective effects. The extended-release formulation ensures a sustained therapeutic effect, improving patient compliance by allowing once-daily dosing. Livcilno M is indicated for the management of essential hypertension, especially in patients requiring dual mechanism therapy to achieve optimal blood pressure control. It may also be beneficial in patients with concomitant cardiovascular conditions such as angina pectoris or heart failure, under medical supervision. Common side effects may include dizziness, fatigue, headache, and peripheral edema; however, the combination is generally well tolerated. Caution is advised in patients with bradycardia, heart block, or severe hepatic impairment. Livcilno M should be used under the guidance of a healthcare professional, with regular monitoring of blood pressure and heart rate to ensure efficacy and safety.